Arcturus Therapeutics (NASDAQ:ARCT) Issues Earnings Results, Misses Expectations By $0.78 EPS

Arcturus Therapeutics (NASDAQ:ARCT) issued its earnings results on Thursday. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78), Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

Arcturus Therapeutics Trading Down 0.5 %

Shares of ARCT stock traded down $0.08 during trading hours on Thursday, reaching $15.97. 296,381 shares of the company’s stock were exchanged, compared to its average volume of 412,633. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00. The stock has a market cap of $432.58 million, a PE ratio of -7.19 and a beta of 2.62. The stock’s fifty day moving average price is $17.02 and its two-hundred day moving average price is $18.66.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Finally, BTIG Research started coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $65.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.